CCO Oncology Podcast

Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

Episode Summary

In this podcast episode, listen to Susana Banerjee, MBBS, MA, PhD, FRCP, and Mansoor Raza Mirza, MD, share their thoughts on trials of interest for ovarian and cervical cancer presented at the IGCS 2022 Annual Global Meeting, including results from the highly anticipated CALLA trial, final OS analyses for ARIEL3, outcomes by previous lines of therapy from SOLO3, and results from the retrospective NeCTuR trial of topotecan, paclitaxel, and bevacizumab in neuroendocrine cervix cancer.

Episode Notes

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:

• Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer
• Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer
• Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer
• Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix

Presenters:

Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist and Research Lead
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv